Article
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Rating:
0.0
Views:
65
Likes:
1
Library:
1
Early trial data shows that a combination of Mirati Therapeutics experimental drug adagrasib and Merck & Co's immunotherapy Keytruda helped about half of previously untreated metastatic lung cancer patients, with manageable side effects, Mirati said on Monday.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value